They discovered that the gene that makes the protein is amplified — duplicated many times over — in these cancer cells, which allows them to produce excess amounts of the oncogenic protein.
The study, reported in the May 7 issue of the American Journal of Pathology, found a direct association between the number of Stat5 genes in human prostate cancer cells and Stat5 protein levels, and also revealed that gene amplification and protein levels increased as prostate cancer metastasized and became resistant to castration (anti-androgen) therapy.
The finding is important since agents that inhibit the Stat5 pathway are currently entering clinical trials, says the study's senior author, Marja Nevalainen, M.D., Ph.D., associate professor of Cancer Biology, Medical Oncology, and Urology at Jefferson.
"Our latest findings on Stat5 provide further support for the idea that targeting Stat5 protein pharmacologically might provide powerful therapy for advanced prostate cancer," she says. "Our hope is that a successful agent might prevent some prostate tumors from spreading and might be able to contain metastasis that has already occurred and become castrate-resistant."
The discovery also suggests that testing Stat5 gene amplification in patients could provide a biomarker that identifies those patients most likely to respond to Stat5 inhibition, Dr. Nevalainen says.
Not only is Dr. Nevalainen testing Stat5 inhibitors developed by Astra Zeneca and Novartis in preclinical studies, her lab has also developed its own inhibitor, which is also being tested.
Dr. Nevalainen has long studied Stat5 in prostate cancer, and with her colleagues, has authored a number of crucial studies demonstrating the impact the gene and its protein can have on prostate cancer progression. "Stat5 isn't the only protein that drives prostate cancer, but it is a very important one," she says.
Stat5 is a transcription factor – a protein that can regulate expression of other genes. In 2003, Dr. Nevalainen discovered that Stat5 protein is critical for viability of prostate cancer cells and growth of prostate tumors in mice. In 2004, Dr. Nevalainen found that Stat5 inside a cell's nucleus is often over-expressed in high-grade human prostate cancer, and in 2005, she demonstrated that Stat5 activity was associated with recurrence of prostate cancer in patients who had already been treated. Then, in 2008 she showed that nuclear Stat5 was especially prevalent in recurrent prostate cancers that are resistant to hormone therapy. Most importantly, her research has demonstrated that blocking Stat5 in laboratory and in animal models effectively destroyed prostate cancer. "We know that Stat5 is absolutely critical to the survival of prostate cancer cells," she says.
In 2010, Dr. Nevalainen found that excess Stat5 in prostate cancer cells is linked to metastasis, and excess Stat5 expression predicts early disease recurrence and death from prostate cancer. This study was conducted to investigate why such over-expression of the protein occurs.
The researchers found amplification of the Stat5 gene in a significant fraction of 128 prostate cancer specimens from patients, and that Stat5 gene amplification was more frequently found in metastatic cancers that are no longer responsible to castration treatment (29 percent) and in high histological grade cancers (40 percent). Experiments in cell culture and in mice showed that increased Stat5 copy numbers conferred a growth advantage for tumors.
"Lots of cancers have chromosomal rearrangements that lead to amplification of pro-growth genes," says Dr. Nevalainen. "We don't know exactly why this happens, but it is related to imperfect cell division and unstable genomes."
While it is known that excess Stat5 protein predicts early recurrence of prostate cancer, development of metastatic disease and death from prostate cancer, researchers will need to determine if Stat5 gene amplification is also linked to those outcomes, she adds.
Researchers who contributed to the study included investigators from Georgetown University, the University of Helsinki in Finland, the University of Basel in Switzerland, and the University of Tampere in Finland. The authors declare no conflicts of interest.
The work was supported by grants from the National Institutes of Health, and the Academy of Finland.
Thomas Jefferson University (TJU), the largest freestanding academic medical center in Philadelphia, is nationally renowned for medical and health sciences education and innovative research. Founded in 1824, TJU includes Jefferson Medical College (JMC), one of the largest private medical schools in the country and ranked among the nation's best medical schools by U.S. News & World Report, and the Jefferson Schools of Nursing, Pharmacy, Health Professions, Population Health and the Graduate School of Biomedical Sciences. Jefferson University Physicians is TJU's multi-specialty physician practice consisting of the full-time faculty of JMC. Thomas Jefferson University partners with its clinical affiliate, Thomas Jefferson University Hospitals.
Jackie Kozloski | EurekAlert!
'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton
A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.
Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
19.09.2017 | Event News
19.09.2017 | Physics and Astronomy
19.09.2017 | Power and Electrical Engineering